US3773919A
(en)
|
1969-10-23 |
1973-11-20 |
Du Pont |
Polylactide-drug mixtures
|
CU22545A1
(es)
|
1994-11-18 |
1999-03-31 |
Centro Inmunologia Molecular |
Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
|
US3896111A
(en)
|
1973-02-20 |
1975-07-22 |
Research Corp |
Ansa macrolides
|
US4151042A
(en)
|
1977-03-31 |
1979-04-24 |
Takeda Chemical Industries, Ltd. |
Method for producing maytansinol and its derivatives
|
US4137230A
(en)
|
1977-11-14 |
1979-01-30 |
Takeda Chemical Industries, Ltd. |
Method for the production of maytansinoids
|
US4265814A
(en)
|
1978-03-24 |
1981-05-05 |
Takeda Chemical Industries |
Matansinol 3-n-hexadecanoate
|
US4307016A
(en)
|
1978-03-24 |
1981-12-22 |
Takeda Chemical Industries, Ltd. |
Demethyl maytansinoids
|
JPS5562090A
(en)
|
1978-10-27 |
1980-05-10 |
Takeda Chem Ind Ltd |
Novel maytansinoid compound and its preparation
|
JPS55164687A
(en)
|
1979-06-11 |
1980-12-22 |
Takeda Chem Ind Ltd |
Novel maytansinoid compound and its preparation
|
JPS5566585A
(en)
|
1978-11-14 |
1980-05-20 |
Takeda Chem Ind Ltd |
Novel maytansinoid compound and its preparation
|
US4256746A
(en)
|
1978-11-14 |
1981-03-17 |
Takeda Chemical Industries |
Dechloromaytansinoids, their pharmaceutical compositions and method of use
|
JPS55102583A
(en)
|
1979-01-31 |
1980-08-05 |
Takeda Chem Ind Ltd |
20-acyloxy-20-demethylmaytansinoid compound
|
JPS55162791A
(en)
|
1979-06-05 |
1980-12-18 |
Takeda Chem Ind Ltd |
Antibiotic c-15003pnd and its preparation
|
JPS55164685A
(en)
|
1979-06-08 |
1980-12-22 |
Takeda Chem Ind Ltd |
Novel maytansinoid compound and its preparation
|
JPS55164686A
(en)
|
1979-06-11 |
1980-12-22 |
Takeda Chem Ind Ltd |
Novel maytansinoid compound and its preparation
|
US4309428A
(en)
|
1979-07-30 |
1982-01-05 |
Takeda Chemical Industries, Ltd. |
Maytansinoids
|
JPS5645483A
(en)
|
1979-09-19 |
1981-04-25 |
Takeda Chem Ind Ltd |
C-15003phm and its preparation
|
EP0028683A1
(en)
|
1979-09-21 |
1981-05-20 |
Takeda Chemical Industries, Ltd. |
Antibiotic C-15003 PHO and production thereof
|
JPS5645485A
(en)
|
1979-09-21 |
1981-04-25 |
Takeda Chem Ind Ltd |
Production of c-15003pnd
|
US4935341A
(en)
|
1986-06-04 |
1990-06-19 |
Whitehead Institute For Biomedical Research |
Detection of point mutations in neu genes
|
WO1982001188A1
(en)
|
1980-10-08 |
1982-04-15 |
Takeda Chemical Industries Ltd |
4,5-deoxymaytansinoide compounds and process for preparing same
|
US4450254A
(en)
|
1980-11-03 |
1984-05-22 |
Standard Oil Company |
Impact improvement of high nitrile resins
|
US4313946A
(en)
|
1981-01-27 |
1982-02-02 |
The United States Of America As Represented By The Secretary Of Agriculture |
Chemotherapeutically active maytansinoids from Trewia nudiflora
|
US4315929A
(en)
|
1981-01-27 |
1982-02-16 |
The United States Of America As Represented By The Secretary Of Agriculture |
Method of controlling the European corn borer with trewiasine
|
JPS57192389A
(en)
|
1981-05-20 |
1982-11-26 |
Takeda Chem Ind Ltd |
Novel maytansinoid
|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
US6054561A
(en)
*
|
1984-02-08 |
2000-04-25 |
Chiron Corporation |
Antigen-binding sites of antibody molecules specific for cancer antigens
|
US4943533A
(en)
|
1984-03-01 |
1990-07-24 |
The Regents Of The University Of California |
Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor
|
US4970198A
(en)
|
1985-10-17 |
1990-11-13 |
American Cyanamid Company |
Antitumor antibiotics (LL-E33288 complex)
|
US7838216B1
(en)
|
1986-03-05 |
2010-11-23 |
The United States Of America, As Represented By The Department Of Health And Human Services |
Human gene related to but distinct from EGF receptor gene
|
US5401638A
(en)
|
1986-06-04 |
1995-03-28 |
Oncogene Science, Inc. |
Detection and quantification of neu related proteins in the biological fluids of humans
|
US4968603A
(en)
|
1986-12-31 |
1990-11-06 |
The Regents Of The University Of California |
Determination of status in neoplastic disease
|
IL85035A0
(en)
|
1987-01-08 |
1988-06-30 |
Int Genetic Eng |
Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
|
US5079233A
(en)
|
1987-01-30 |
1992-01-07 |
American Cyanamid Company |
N-acyl derivatives of the LL-E33288 antitumor antibiotics, composition and methods for using the same
|
EP0307434B2
(en)
|
1987-03-18 |
1998-07-29 |
Scotgen Biopharmaceuticals, Inc. |
Altered antibodies
|
US4975278A
(en)
|
1988-02-26 |
1990-12-04 |
Bristol-Myers Company |
Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
|
US5053394A
(en)
|
1988-09-21 |
1991-10-01 |
American Cyanamid Company |
Targeted forms of methyltrithio antitumor agents
|
US5770701A
(en)
|
1987-10-30 |
1998-06-23 |
American Cyanamid Company |
Process for preparing targeted forms of methyltrithio antitumor agents
|
US5606040A
(en)
|
1987-10-30 |
1997-02-25 |
American Cyanamid Company |
Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group
|
US5824311A
(en)
|
1987-11-30 |
1998-10-20 |
Trustees Of The University Of Pennsylvania |
Treatment of tumors with monoclonal antibodies against oncogene antigens
|
US5720937A
(en)
|
1988-01-12 |
1998-02-24 |
Genentech, Inc. |
In vivo tumor detection assay
|
WO1989006692A1
(en)
|
1988-01-12 |
1989-07-27 |
Genentech, Inc. |
Method of treating tumor cells by inhibiting growth factor receptor function
|
JPH03505964A
(ja)
|
1988-04-18 |
1991-12-26 |
アプライド・バイオテクノロジー・インコーポレーテッド |
neu遺伝子の発現及び遺伝子産物の検出
|
AU4128089A
(en)
*
|
1988-09-15 |
1990-03-22 |
Rorer International (Overseas) Inc. |
Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same
|
GB8823869D0
(en)
|
1988-10-12 |
1988-11-16 |
Medical Res Council |
Production of antibodies
|
US5175384A
(en)
|
1988-12-05 |
1992-12-29 |
Genpharm International |
Transgenic mice depleted in mature t-cells and methods for making transgenic mice
|
US5530101A
(en)
|
1988-12-28 |
1996-06-25 |
Protein Design Labs, Inc. |
Humanized immunoglobulins
|
WO1990014357A1
(en)
|
1989-05-19 |
1990-11-29 |
Genentech, Inc. |
Her2 extracellular domain
|
DE3920358A1
(de)
|
1989-06-22 |
1991-01-17 |
Behringwerke Ag |
Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
|
US5705157A
(en)
|
1989-07-27 |
1998-01-06 |
The Trustees Of The University Of Pennsylvania |
Methods of treating cancerous cells with anti-receptor antibodies
|
ATE207958T1
(de)
|
1989-08-04 |
2001-11-15 |
Schering Ag |
Äusserliche domäne von c-erbb-2:gp75
|
US6884418B1
(en)
|
1989-08-04 |
2005-04-26 |
Berlex Laboratories, Inc. |
Use of ligand-mimicking agents and anti-neoplastic drugs in cancer therapy
|
DE69025946T2
(de)
|
1989-09-08 |
1996-10-17 |
Univ Duke |
Modifikationen der struktur des egf-rezeptor-gens in menschlichen glioma
|
EP0494135B1
(en)
|
1989-09-29 |
1996-04-10 |
Oncogene Science, Inc. |
Human "neu" related protein p100 and use of the same for detecting preneoplastic or neoplastic cells in a human
|
US5208020A
(en)
|
1989-10-25 |
1993-05-04 |
Immunogen Inc. |
Cytotoxic agents comprising maytansinoids and their therapeutic use
|
CA2026147C
(en)
|
1989-10-25 |
2006-02-07 |
Ravi J. Chari |
Cytotoxic agents comprising maytansinoids and their therapeutic use
|
US5959177A
(en)
|
1989-10-27 |
1999-09-28 |
The Scripps Research Institute |
Transgenic plants expressing assembled secretory antibodies
|
US5183884A
(en)
*
|
1989-12-01 |
1993-02-02 |
United States Of America |
Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor
|
AU633698B2
(en)
|
1990-01-12 |
1993-02-04 |
Amgen Fremont Inc. |
Generation of xenogeneic antibodies
|
US5661016A
(en)
|
1990-08-29 |
1997-08-26 |
Genpharm International Inc. |
Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
|
US5625126A
(en)
|
1990-08-29 |
1997-04-29 |
Genpharm International, Inc. |
Transgenic non-human animals for producing heterologous antibodies
|
WO1992003918A1
(en)
|
1990-08-29 |
1992-03-19 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
US5633425A
(en)
|
1990-08-29 |
1997-05-27 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
US5545806A
(en)
|
1990-08-29 |
1996-08-13 |
Genpharm International, Inc. |
Ransgenic non-human animals for producing heterologous antibodies
|
AU662311B2
(en)
|
1991-02-05 |
1995-08-31 |
Novartis Ag |
Recombinant antibodies specific for a growth factor receptor
|
US5571894A
(en)
|
1991-02-05 |
1996-11-05 |
Ciba-Geigy Corporation |
Recombinant antibodies specific for a growth factor receptor
|
IL101943A0
(en)
|
1991-05-24 |
1992-12-30 |
Genentech Inc |
Structure,production and use of heregulin
|
US6800738B1
(en)
|
1991-06-14 |
2004-10-05 |
Genentech, Inc. |
Method for making humanized antibodies
|
WO1994004679A1
(en)
|
1991-06-14 |
1994-03-03 |
Genentech, Inc. |
Method for making humanized antibodies
|
EP1400536A1
(en)
|
1991-06-14 |
2004-03-24 |
Genentech Inc. |
Method for making humanized antibodies
|
US5939531A
(en)
|
1991-07-15 |
1999-08-17 |
Novartis Corp. |
Recombinant antibodies specific for a growth factor receptor
|
ES2129454T3
(es)
|
1991-08-22 |
1999-06-16 |
Becton Dickinson Co |
Procedimientos y composiciones de tratamientos de cancer y pronostico de reacciones a los indicados tratamientos.
|
EP0861893A3
(en)
|
1991-09-19 |
1999-11-10 |
Genentech, Inc. |
High level expression of immunoglobulin polypeptides
|
US5362852A
(en)
|
1991-09-27 |
1994-11-08 |
Pfizer Inc. |
Modified peptide derivatives conjugated at 2-hydroxyethylamine moieties
|
US5288477A
(en)
|
1991-09-27 |
1994-02-22 |
Becton, Dickinson And Company |
Method for prognosticating response to cancer therapy
|
US5587458A
(en)
|
1991-10-07 |
1996-12-24 |
Aronex Pharmaceuticals, Inc. |
Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
|
DK1136556T3
(da)
|
1991-11-25 |
2005-10-03 |
Enzon Inc |
Fremgangsmåde til fremstilling af multivalente antigen-bindende proteiner
|
WO1993012220A1
(en)
|
1991-12-12 |
1993-06-24 |
Berlex Laboratories, Inc. |
RECOMBINANT AND CHIMERIC ANTIBODIES TO c-erbB-2
|
AU661533B2
(en)
|
1992-01-20 |
1995-07-27 |
Astrazeneca Ab |
Quinazoline derivatives
|
AU675929B2
(en)
|
1992-02-06 |
1997-02-27 |
Curis, Inc. |
Biosynthetic binding protein for cancer marker
|
WO1993021319A1
(en)
|
1992-04-08 |
1993-10-28 |
Cetus Oncology Corporation |
HUMANIZED C-erbB-2 SPECIFIC ANTIBODIES
|
ZA932522B
(en)
|
1992-04-10 |
1993-12-20 |
Res Dev Foundation |
Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens
|
JPH08504172A
(ja)
|
1992-06-30 |
1996-05-07 |
オンコロジクス,インコーポレイティド |
抗−erbB−2モノクロナール抗体の組み合わせ物及び使用方法
|
AU5355594A
(en)
|
1992-10-09 |
1994-05-09 |
Oncor, Inc. |
Methods for the detection of chromosome structural abnormalities by (in situ) hybridization to fixed tissue
|
EP0752248B1
(en)
|
1992-11-13 |
2000-09-27 |
Idec Pharmaceuticals Corporation |
Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
|
CA2103323A1
(en)
|
1992-11-24 |
1994-05-25 |
Gregory D. Plowman |
Her4 human receptor tyrosine kinase
|
US5635483A
(en)
|
1992-12-03 |
1997-06-03 |
Arizona Board Of Regents Acting On Behalf Of Arizona State University |
Tumor inhibiting tetrapeptide bearing modified phenethyl amides
|
US5780588A
(en)
|
1993-01-26 |
1998-07-14 |
Arizona Board Of Regents |
Elucidation and synthesis of selected pentapeptides
|
PT616812E
(pt)
|
1993-03-24 |
2000-04-28 |
Berlex Biosciences |
Combinacao de compostos anti-hormonais e moleculas de ligacao no tratamento do cancro
|
AU6527894A
(en)
|
1993-03-30 |
1994-10-24 |
Trustees Of The University Of Pennsylvania, The |
Prevention of tumors with monoclonal antibodies against (neu)
|
JPH08511420A
(ja)
|
1993-06-16 |
1996-12-03 |
セルテック・セラピューテイクス・リミテッド |
抗 体
|
GB9314893D0
(en)
|
1993-07-19 |
1993-09-01 |
Zeneca Ltd |
Quinazoline derivatives
|
DE69428764T2
(de)
|
1993-12-24 |
2002-06-20 |
Merck Patent Gmbh |
Immunokonjugate
|
US5654307A
(en)
|
1994-01-25 |
1997-08-05 |
Warner-Lambert Company |
Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family
|
IL112249A
(en)
|
1994-01-25 |
2001-11-25 |
Warner Lambert Co |
Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
|
IL112248A0
(en)
|
1994-01-25 |
1995-03-30 |
Warner Lambert Co |
Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
|
US6524832B1
(en)
*
|
1994-02-04 |
2003-02-25 |
Arch Development Corporation |
DNA damaging agents in combination with tyrosine kinase inhibitors
|
US20030108545A1
(en)
|
1994-02-10 |
2003-06-12 |
Patricia Rockwell |
Combination methods of inhibiting tumor growth with a vascular endothelial growth factor receptor antagonist
|
US6811779B2
(en)
|
1994-02-10 |
2004-11-02 |
Imclone Systems Incorporated |
Methods for reducing tumor growth with VEGF receptor antibody combined with radiation and chemotherapy
|
US5773001A
(en)
|
1994-06-03 |
1998-06-30 |
American Cyanamid Company |
Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
|
US5910486A
(en)
|
1994-09-06 |
1999-06-08 |
Uab Research Foundation |
Methods for modulating protein function in cells using, intracellular antibody homologues
|
US5804396A
(en)
|
1994-10-12 |
1998-09-08 |
Sugen, Inc. |
Assay for agents active in proliferative disorders
|
US5846749A
(en)
|
1994-10-12 |
1998-12-08 |
The Regents Of The University Of California |
Quantitative measurement of tissue protein identified by immunohistochemistry and standardized protein determination
|
US5789199A
(en)
|
1994-11-03 |
1998-08-04 |
Genentech, Inc. |
Process for bacterial production of polypeptides
|
US6214388B1
(en)
|
1994-11-09 |
2001-04-10 |
The Regents Of The University Of California |
Immunoliposomes that optimize internalization into target cells
|
DE69504278T2
(de)
|
1994-11-10 |
1999-05-06 |
Univ Eberhard Karls |
Verfahren zur Wachstumshemmung von Leukämischen Zellen durch HER-2-Protein-Zeilen
|
AU4289496A
(en)
|
1994-12-02 |
1996-06-19 |
Chiron Corporation |
Method of promoting an immune response with a bispecific antibody
|
US5663149A
(en)
|
1994-12-13 |
1997-09-02 |
Arizona Board Of Regents Acting On Behalf Of Arizona State University |
Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides
|
US5840523A
(en)
|
1995-03-01 |
1998-11-24 |
Genetech, Inc. |
Methods and compositions for secretion of heterologous polypeptides
|
US5641870A
(en)
|
1995-04-20 |
1997-06-24 |
Genentech, Inc. |
Low pH hydrophobic interaction chromatography for antibody purification
|
US5783404A
(en)
|
1995-04-13 |
1998-07-21 |
Amgen Inc. |
Methods and compositions for determining HER-2/neu expression using monoclonal antibodies
|
EP1978033A3
(en)
|
1995-04-27 |
2008-12-24 |
Amgen Fremont Inc. |
Human antibodies derived from immunized xenomice
|
GB9508538D0
(en)
|
1995-04-27 |
1995-06-14 |
Zeneca Ltd |
Quinazoline derivatives
|
CA2219486A1
(en)
|
1995-04-28 |
1996-10-31 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
US5747498A
(en)
|
1996-05-28 |
1998-05-05 |
Pfizer Inc. |
Alkynyl and azido-substituted 4-anilinoquinazolines
|
AU6267896A
(en)
|
1995-06-07 |
1996-12-30 |
Imclone Systems Incorporated |
Antibody and antibody fragments for inhibiting the growth oftumors
|
US6410690B1
(en)
|
1995-06-07 |
2002-06-25 |
Medarex, Inc. |
Therapeutic compounds comprised of anti-Fc receptor antibodies
|
US5714586A
(en)
|
1995-06-07 |
1998-02-03 |
American Cyanamid Company |
Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
|
US5712374A
(en)
|
1995-06-07 |
1998-01-27 |
American Cyanamid Company |
Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
|
EP2258726A1
(en)
|
1995-06-14 |
2010-12-08 |
The Regents of the University of California |
High affinity human antibodies to c-erbB-2
|
SK398A3
(en)
|
1995-07-06 |
1998-07-08 |
Novartis Ag |
Pyrrolopyrimidines and processes for the preparation thereof
|
US6267958B1
(en)
|
1995-07-27 |
2001-07-31 |
Genentech, Inc. |
Protein formulation
|
US6685940B2
(en)
|
1995-07-27 |
2004-02-03 |
Genentech, Inc. |
Protein formulation
|
DE19544393A1
(de)
|
1995-11-15 |
1997-05-22 |
Hoechst Schering Agrevo Gmbh |
Synergistische herbizide Mischungen
|
US5783186A
(en)
|
1995-12-05 |
1998-07-21 |
Amgen Inc. |
Antibody-induced apoptosis
|
US5760041A
(en)
|
1996-02-05 |
1998-06-02 |
American Cyanamid Company |
4-aminoquinazoline EGFR Inhibitors
|
GB9603095D0
(en)
|
1996-02-14 |
1996-04-10 |
Zeneca Ltd |
Quinazoline derivatives
|
GB9603256D0
(en)
|
1996-02-16 |
1996-04-17 |
Wellcome Found |
Antibodies
|
US5968511A
(en)
|
1996-03-27 |
1999-10-19 |
Genentech, Inc. |
ErbB3 antibodies
|
TW517061B
(en)
*
|
1996-03-29 |
2003-01-11 |
Pharmacia & Amp Upjohn Ab |
Modified/chimeric superantigens and their use
|
RO121900B1
(ro)
|
1996-04-12 |
2008-07-30 |
Warner-Lambert Company |
Compuşi inhibitori, ireversibili, ai tirozin kinazelor, compoziţie farmaceutică care îi conţine şi utilizarea acestora
|
US5925519A
(en)
|
1996-06-03 |
1999-07-20 |
The Regents Of The University Of California |
Genetic alterations associated with prostate cancer
|
US5922845A
(en)
|
1996-07-11 |
1999-07-13 |
Medarex, Inc. |
Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies
|
AR007857A1
(es)
|
1996-07-13 |
1999-11-24 |
Glaxo Group Ltd |
Compuestos heterociclicos fusionados como inhibidores de proteina tirosina quinasa, sus metodos de preparacion, intermediarios uso en medicina ycomposiciones farmaceuticas que los contienen.
|
ID18494A
(id)
|
1996-10-02 |
1998-04-16 |
Novartis Ag |
Turunan pirazola leburan dan proses pembuatannya
|
AU4982097A
(en)
|
1996-10-18 |
1998-05-15 |
Board Of Regents, The University Of Texas System |
Anti-erbb2 antibodies
|
US6468547B1
(en)
|
1996-10-30 |
2002-10-22 |
Uab Research Foundation |
Enhancement of tumor cell chemosensitivity and radiosensitivity using single chain secretory antibodies
|
AU5243198A
(en)
|
1996-10-30 |
1998-05-22 |
Uab Research Foundation, The |
Enhancement of tumor cell chemosensitivity and radiosensitivity using single chain intracellular antibodies
|
IL130061A
(en)
|
1996-11-27 |
2001-09-13 |
Genentech Inc |
Affinity purification of polypeptide on protein a matrix
|
CA2616914C
(en)
|
1996-12-03 |
2012-05-29 |
Abgenix, Inc. |
Egfr-binding antibody
|
EP1012275A1
(en)
|
1997-01-31 |
2000-06-28 |
University Of Rochester |
Chimeric antibody fusion proteins for the recruitment and stimulation of an antitumor immune response
|
US6002008A
(en)
|
1997-04-03 |
1999-12-14 |
American Cyanamid Company |
Substituted 3-cyano quinolines
|
US20020076695A1
(en)
|
1997-04-04 |
2002-06-20 |
Jeffrey S. Ross |
Methods for treating prostate cancer
|
US5994071A
(en)
|
1997-04-04 |
1999-11-30 |
Albany Medical College |
Assessment of prostate cancer
|
US6235883B1
(en)
|
1997-05-05 |
2001-05-22 |
Abgenix, Inc. |
Human monoclonal antibodies to epidermal growth factor receptor
|
AU7165698A
(en)
|
1997-05-06 |
1998-11-27 |
American Cyanamid Company |
Use of quinazoline compounds for the treatment of polycystic kidney disease
|
ATE296315T1
(de)
|
1997-06-24 |
2005-06-15 |
Genentech Inc |
Galactosylierte glykoproteine enthaltende zusammensetzungen und verfahren zur deren herstellung
|
TW436485B
(en)
|
1997-08-01 |
2001-05-28 |
American Cyanamid Co |
Substituted quinazoline derivatives
|
US6040498A
(en)
|
1998-08-11 |
2000-03-21 |
North Caroline State University |
Genetically engineered duckweed
|
WO1999019488A1
(en)
|
1997-10-15 |
1999-04-22 |
Children's Medical Center Corporation |
Novel human egf receptors and use thereof
|
ATE419009T1
(de)
|
1997-10-31 |
2009-01-15 |
Genentech Inc |
Methoden und zusammensetzungen bestehend aus glykoprotein-glykoformen
|
PL340800A1
(en)
|
1997-11-06 |
2001-02-26 |
American Cyanamid Co |
Application of quinazoline derivatives as inhibitors of thyrosinic kinase in treating colonic polyps
|
ZA9811162B
(en)
|
1997-12-12 |
2000-06-07 |
Genentech Inc |
Treatment with anti-ERBB2 antibodies.
|
RS49779B
(sr)
*
|
1998-01-12 |
2008-06-05 |
Glaxo Group Limited, |
Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze
|
US6358682B1
(en)
|
1998-01-26 |
2002-03-19 |
Ventana Medical Systems, Inc. |
Method and kit for the prognostication of breast cancer
|
US6417168B1
(en)
|
1998-03-04 |
2002-07-09 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods of treating tumors
|
US20020192211A1
(en)
|
1998-03-17 |
2002-12-19 |
Hudziak Robert M. |
Method of treating tumor cells by inhibiting growth factor receptor function
|
EP1064027B1
(en)
|
1998-03-27 |
2008-06-18 |
Genentech, Inc. |
Apo-2 ligand-anti-her-2 antibody synergism
|
EP1068241B1
(en)
|
1998-04-02 |
2007-10-10 |
Genentech, Inc. |
Antibody variants and fragments thereof
|
US6194551B1
(en)
|
1998-04-02 |
2001-02-27 |
Genentech, Inc. |
Polypeptide variants
|
PT1071700E
(pt)
|
1998-04-20 |
2010-04-23 |
Glycart Biotechnology Ag |
Modificação por glicosilação de anticorpos para melhorar a citotoxicidade celular dependente de anticorpos
|
US7244826B1
(en)
|
1998-04-24 |
2007-07-17 |
The Regents Of The University Of California |
Internalizing ERB2 antibodies
|
BRPI9910332B8
(pt)
|
1998-05-06 |
2021-05-25 |
Genentech Inc |
método para purificação de um polipeptídio a partir de uma composição
|
PL348634A1
(en)
|
1998-05-15 |
2002-06-03 |
Imclone Systems Inc |
Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases
|
US6573043B1
(en)
|
1998-10-07 |
2003-06-03 |
Genentech, Inc. |
Tissue analysis and kits therefor
|
WO2000031048A1
(en)
|
1998-11-19 |
2000-06-02 |
Warner-Lambert Company |
N-[4-(3-chloro-4-fluoro-phenylamino)-7-(3-morpholin-4-yl-propoxy)-quinazolin-6-yl]-acrylamide, an irreversible inhibitor of tyrosine kinases
|
US6737056B1
(en)
|
1999-01-15 |
2004-05-18 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
KR100940380B1
(ko)
|
1999-01-15 |
2010-02-02 |
제넨테크, 인크. |
효과기 기능이 변화된 폴리펩티드 변이체
|
CA2357525A1
(en)
|
1999-01-27 |
2000-08-03 |
Cornell Research Foundation, Inc. |
Treating cancers associated with overexpression of her-2/neu
|
US6316462B1
(en)
|
1999-04-09 |
2001-11-13 |
Schering Corporation |
Methods of inducing cancer cell death and tumor regression
|
ES2571230T3
(es)
|
1999-04-09 |
2016-05-24 |
Kyowa Hakko Kirin Co Ltd |
Procedimiento para controlar la actividad de una molécula inmunofuncional
|
US6333348B1
(en)
|
1999-04-09 |
2001-12-25 |
Aventis Pharma S.A. |
Use of docetaxel for treating cancers
|
EE200100603A
(et)
*
|
1999-05-14 |
2003-02-17 |
Imclone Systems Incorporated |
Inimese refraktaarsete kasvajate ravi epidermaalse kasvufaktori retseptori antagonistidega
|
CA2374085C
(en)
|
1999-05-14 |
2015-12-29 |
Genentech, Inc. |
Tumour treatment with anti-erbb2 antibodies
|
AUPQ105799A0
(en)
|
1999-06-18 |
1999-07-08 |
Victor Chang Cardiac Research Institute, The |
Cell growth inhibition
|
US6949245B1
(en)
*
|
1999-06-25 |
2005-09-27 |
Genentech, Inc. |
Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
|
CN100482281C
(zh)
|
1999-06-25 |
2009-04-29 |
基因技术股份有限公司 |
抗ErbB抗体-类美坦素偶联物在制备药物中的应用
|
US20030086924A1
(en)
|
1999-06-25 |
2003-05-08 |
Genentech, Inc. |
Treatment with anti-ErbB2 antibodies
|
CN100381172C
(zh)
|
1999-06-25 |
2008-04-16 |
吉尼泰克公司 |
使用抗-ErbB2抗体治疗前列腺癌
|
AU784045B2
(en)
|
1999-06-25 |
2006-01-19 |
Genentech Inc. |
Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
|
US20040013667A1
(en)
|
1999-06-25 |
2004-01-22 |
Genentech, Inc. |
Treatment with anti-ErbB2 antibodies
|
GB9917012D0
(en)
|
1999-07-20 |
1999-09-22 |
Pharmacia & Upjohn Spa |
Combined preparations comprising antitumor agents
|
JP2003516718A
(ja)
|
1999-07-29 |
2003-05-20 |
メダレックス インク |
HER2/neuに対するヒトモノクローナル抗体
|
US6627196B1
(en)
|
1999-08-27 |
2003-09-30 |
Genentech, Inc. |
Dosages for treatment with anti-ErbB2 antibodies
|
WO2001021192A2
(en)
|
1999-09-22 |
2001-03-29 |
Corixa Corporation |
Methods for diagnosis and therapy of hematological and virus-associated malignancies
|
KR100797667B1
(ko)
|
1999-10-04 |
2008-01-23 |
메디카고 인코포레이티드 |
외래 유전자의 전사를 조절하는 방법
|
US7125978B1
(en)
|
1999-10-04 |
2006-10-24 |
Medicago Inc. |
Promoter for regulating expression of foreign genes
|
JP4668498B2
(ja)
|
1999-10-19 |
2011-04-13 |
協和発酵キリン株式会社 |
ポリペプチドの製造方法
|
GB9925958D0
(en)
|
1999-11-02 |
1999-12-29 |
Bundred Nigel J |
Therapeutic use
|
US20020041865A1
(en)
|
2000-01-20 |
2002-04-11 |
Richard Austin |
Methods for treating tumors
|
US20030022918A1
(en)
|
2000-02-29 |
2003-01-30 |
Horak Ivan David |
Farnesyl protein transferase inhibitor combinations with an her2 antibody
|
US6632979B2
(en)
|
2000-03-16 |
2003-10-14 |
Genentech, Inc. |
Rodent HER2 tumor model
|
US7097840B2
(en)
|
2000-03-16 |
2006-08-29 |
Genentech, Inc. |
Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
|
US6767541B2
(en)
|
2000-03-20 |
2004-07-27 |
The Regents Of The University Of California |
HER-2/neu overexpression abrogates growth inhibitory pathways
|
US20030152572A1
(en)
|
2000-04-06 |
2003-08-14 |
Yoshimi Homma |
Diagnostic and therapeutic agents for rheumatoid arthritis
|
GB0008368D0
(en)
|
2000-04-06 |
2000-05-24 |
Astrazeneca Ab |
Combination product
|
NZ521540A
(en)
*
|
2000-04-11 |
2004-09-24 |
Genentech Inc |
Multivalent antibodies and uses therefor
|
US7306801B2
(en)
|
2000-05-15 |
2007-12-11 |
Health Research, Inc. |
Methods of therapy for cancers characterized by overexpression of the HER2 receptor protein
|
HUP0301877A2
(hu)
|
2000-05-15 |
2003-09-29 |
Pharmacia & Upjohn Co. |
Aromatáz inhibitorok és monoklonális anti-HER2 ellenanyagok mint tumorellenes szerek
|
ATE441433T1
(de)
|
2000-05-19 |
2009-09-15 |
Genentech Inc |
Gennachweisverfahren zur verbesserung der wahrscheinlichkeit einer wirkungsvollen antwort auf eine krebstherapie mit einem erbb- antagonisten
|
GB0017635D0
(en)
|
2000-07-18 |
2000-09-06 |
Pharmacia & Upjohn Spa |
Antitumor combined therapy
|
TWI317285B
(en)
|
2000-07-28 |
2009-11-21 |
Dainippon Sumitomo Pharma Co |
New use and kit for remedies for cancer
|
WO2002011677A2
(en)
|
2000-08-09 |
2002-02-14 |
Imclone Systems Incorporated |
Treatment of hyperproliferative diseases with epidermal growth factor receptor antagonists
|
US6984494B2
(en)
|
2000-08-15 |
2006-01-10 |
Genentech, Inc. |
Analytical method
|
US20020119148A1
(en)
*
|
2000-09-01 |
2002-08-29 |
Gerritsen Mary E. |
ErbB4 antagonists
|
US6946292B2
(en)
|
2000-10-06 |
2005-09-20 |
Kyowa Hakko Kogyo Co., Ltd. |
Cells producing antibody compositions with increased antibody dependent cytotoxic activity
|
US7064191B2
(en)
|
2000-10-06 |
2006-06-20 |
Kyowa Hakko Kogyo Co., Ltd. |
Process for purifying antibody
|
CN102311986B
(zh)
|
2000-10-06 |
2015-08-19 |
协和发酵麒麟株式会社 |
产生抗体组合物的细胞
|
US7005278B2
(en)
|
2001-03-02 |
2006-02-28 |
Danenberg Kathleen D |
Method of determining dihydropyrimidine dehydrogenase gene expression
|
EP1379686B1
(en)
|
2000-12-01 |
2012-09-05 |
Response Genetics, Inc. |
Method of determining epidermal growth factor receptor and her2-neu gene expression and correlation of levels thereof with survival rates
|
US20020142328A1
(en)
|
2000-12-01 |
2002-10-03 |
Danenberg Kathleen D. |
Method of determining a chemotherapeutic regimen by assaying gene expression in primary tumors
|
US6602670B2
(en)
|
2000-12-01 |
2003-08-05 |
Response Genetics, Inc. |
Method of determining a chemotherapeutic regimen based on ERCC1 expression
|
US6582919B2
(en)
|
2001-06-11 |
2003-06-24 |
Response Genetics, Inc. |
Method of determining epidermal growth factor receptor and HER2-neu gene expression and correlation of levels thereof with survival rates
|
AU2002239486A1
(en)
|
2000-12-08 |
2002-06-18 |
Uab Research Foundation |
Combination radiation therapy and chemotherapy in conjuction with administration of growth factor receptor antibody
|
PL206142B1
(pl)
|
2001-01-09 |
2010-07-30 |
Merck Patent Gmbhmerck Patent Gmbh |
Kompozycja i zestaw farmaceutyczny do leczenia nowotworów i przerzutów nowotworowych oraz ich zastosowanie
|
EP1228766A1
(en)
|
2001-01-31 |
2002-08-07 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
PYK2 phosphorylation by HER3 induces tumor invasion
|
WO2002081649A2
(en)
*
|
2001-04-06 |
2002-10-17 |
The Trustees Of The University Of Pennsylvania |
ErbB INTERFACE PEPTIDOMIMETICS AND METHODS OF USE THEREOF
|
WO2002087619A1
(fr)
|
2001-04-27 |
2002-11-07 |
Takeda Chemical Industries, Ltd. |
Methode de prevention et de traitement du cancer
|
US6884869B2
(en)
|
2001-04-30 |
2005-04-26 |
Seattle Genetics, Inc. |
Pentapeptide compounds and uses related thereto
|
PL363322A1
(en)
|
2001-05-08 |
2004-11-15 |
Merck Patent Gmbh |
Combination therapy using anti-egfr antibodies and anti-hormonal agents
|
ITRM20010408A1
(it)
|
2001-07-10 |
2003-01-10 |
Univ Napoli Federico Ii |
Mini-anticorpo umano citotossico per cellule tumorali che esprimono il recettore erbb2.
|
CA2838062C
(en)
|
2001-08-03 |
2015-12-22 |
Roche Glycart Ag |
Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
|
WO2003012072A2
(en)
|
2001-08-03 |
2003-02-13 |
The Trustees Of The University Of Pennsylvania |
Monoclonal antibodies to activated erbb family members and methods of use thereof
|
EP1283053A1
(en)
|
2001-08-09 |
2003-02-12 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Inhibitors of HER3 activity
|
US20030068318A1
(en)
|
2001-09-28 |
2003-04-10 |
O'brien Timothy |
Treatment of uterine serous papillary cancer
|
AU2002337935B2
(en)
|
2001-10-25 |
2008-05-01 |
Genentech, Inc. |
Glycoprotein compositions
|
US20030096823A1
(en)
|
2001-11-16 |
2003-05-22 |
Beryl Asp |
Method for the treatment of cardiotoxicity induced by antitumor compounds
|
US20040093621A1
(en)
|
2001-12-25 |
2004-05-13 |
Kyowa Hakko Kogyo Co., Ltd |
Antibody composition which specifically binds to CD20
|
US20030175845A1
(en)
|
2002-03-13 |
2003-09-18 |
Kalbag Suresh M. |
Use of sulfitolysis in high performance peptide mapping
|
US7332585B2
(en)
*
|
2002-04-05 |
2008-02-19 |
The Regents Of The California University |
Bispecific single chain Fv antibody molecules and methods of use thereof
|
US7332580B2
(en)
*
|
2002-04-05 |
2008-02-19 |
The Regents Of The University Of California |
Bispecific single chain Fv antibody molecules and methods of use thereof
|
JP2005534623A
(ja)
|
2002-04-08 |
2005-11-17 |
スミスクライン ビーチャム コーポレーション |
Erbファミリーの阻害剤並びにraf及び/又はras阻害剤を投与することを含む癌の治療法
|
AU2003236020B2
(en)
|
2002-04-09 |
2009-03-19 |
Kyowa Hakko Kirin Co., Ltd. |
Cell with depression or deletion of the activity of protein participating in GDP-fucose transport
|
WO2003085118A1
(fr)
|
2002-04-09 |
2003-10-16 |
Kyowa Hakko Kogyo Co., Ltd. |
Procede de production de composition anticorps
|
US20050031613A1
(en)
|
2002-04-09 |
2005-02-10 |
Kazuyasu Nakamura |
Therapeutic agent for patients having human FcgammaRIIIa
|
AU2003236018A1
(en)
|
2002-04-09 |
2003-10-20 |
Kyowa Hakko Kirin Co., Ltd. |
METHOD OF ENHANCING ACTIVITY OF ANTIBODY COMPOSITION OF BINDING TO FcGamma RECEPTOR IIIa
|
JPWO2003084569A1
(ja)
|
2002-04-09 |
2005-08-11 |
協和醗酵工業株式会社 |
抗体組成物含有医薬
|
CN102911987B
(zh)
|
2002-04-09 |
2015-09-30 |
协和发酵麒麟株式会社 |
基因组被修饰的细胞
|
AU2003224916B2
(en)
|
2002-04-10 |
2009-01-08 |
Genentech, Inc. |
Anti-HER2 antibody variants
|
ITTO20020340A1
(it)
|
2002-04-19 |
2003-10-20 |
Biother Di Contardi Gabriella |
Localizzazione del recettore her2 mediante anticorpo umanizzato biotinilato.
|
US20030202973A1
(en)
|
2002-04-29 |
2003-10-30 |
Dr. George Pieczenik |
Treatment of refractory human tumors with epidermal growth factor receptor and HER1 mitogenic ligand (EGFRML) antagonists
|
NZ556507A
(en)
|
2002-06-03 |
2010-03-26 |
Genentech Inc |
Synthetic antibody phage libraries
|
ATE328906T1
(de)
*
|
2002-06-28 |
2006-06-15 |
Domantis Ltd |
Dual-specifische liganden mit erhöhter halbwertszeit
|
HUP0600340A3
(en)
|
2002-07-15 |
2011-06-28 |
Genentech Inc |
Methods for identifying tumors that are responsive to treatment with anti-erbb2 antibodies
|
EP1391213A1
(en)
|
2002-08-21 |
2004-02-25 |
Boehringer Ingelheim International GmbH |
Compositions and methods for treating cancer using maytansinoid CD44 antibody immunoconjugates and chemotherapeutic agents
|
HUE033623T2
(en)
|
2002-09-11 |
2017-12-28 |
Genentech Inc |
protein purification
|
WO2004032961A1
(en)
|
2002-10-10 |
2004-04-22 |
Merck Patent Gmbh |
Bispecific anti-erb-b antibodies and their use in tumor therapy
|
US7361740B2
(en)
|
2002-10-15 |
2008-04-22 |
Pdl Biopharma, Inc. |
Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
|
WO2004048525A2
(en)
|
2002-11-21 |
2004-06-10 |
Genentech, Inc. |
Therapy of non-malignant diseases or disorders with anti-erbb2 antibodies
|
BRPI0316779B1
(pt)
|
2002-12-16 |
2020-04-28 |
Genentech Inc |
anticorpo humanizado que liga cd20 humano, composição, artigo manufaturado, método de indução da apoptose, método de tratamento de câncer cd20 positivo, métodos de tratamento de doenças autoimunes, ácidos nucléicos isolados, vetores de expressão, células hospedeiras, método para a produção de um anticorpo 2h7 humanizado, polipeptídeo isolado, formulação líquida, método de tratamento de artrite reumatóide (ra) e anticorpos de ligação de cd20 humanizados
|
WO2004087207A2
(en)
|
2003-03-27 |
2004-10-14 |
Georgetown University |
Method for inducing apoptosis and aneuploidy regression in cancer cells
|
KR20180132969A
(ko)
|
2003-05-30 |
2018-12-12 |
제넨테크, 인크. |
항-vegf 항체를 사용한 치료
|
CN1838959A
(zh)
*
|
2003-08-18 |
2006-09-27 |
辉瑞产品公司 |
Erbb2抗癌剂的给药方案
|
AU2004279742A1
(en)
|
2003-10-08 |
2005-04-21 |
Kyowa Hakko Kirin Co., Ltd. |
Fused protein composition
|
CA2542125A1
(en)
|
2003-10-09 |
2005-04-21 |
Kyowa Hakko Kogyo Co., Ltd. |
Process for producing antibody composition by using rna inhibiting the function of .alpha.1,6-fucosyltransferase
|
RS58420B1
(sr)
|
2003-11-05 |
2019-04-30 |
Roche Glycart Ag |
Cd20 antitela sa povećanim afinitetom za vezivanje fc receptora i efektornom funkcijom
|
JPWO2005053742A1
(ja)
|
2003-12-04 |
2007-06-28 |
協和醗酵工業株式会社 |
抗体組成物を含有する医薬
|
PL1737891T3
(pl)
|
2004-04-13 |
2013-08-30 |
Hoffmann La Roche |
Przeciwciała przeciw selektynie p
|
US8124085B2
(en)
*
|
2004-05-05 |
2012-02-28 |
Merrimack Pharmaceuticals, Inc. |
Bispecific binding agents for modulating biological activity
|
TWI309240B
(en)
|
2004-09-17 |
2009-05-01 |
Hoffmann La Roche |
Anti-ox40l antibodies
|
CA2580141C
(en)
*
|
2004-09-23 |
2013-12-10 |
Genentech, Inc. |
Cysteine engineered antibodies and conjugates
|
AU2005323025A1
(en)
|
2004-12-31 |
2006-07-13 |
Biogen Idec Ma Inc. |
Polypeptides that bind BR3 and uses thereof
|
ZA200706017B
(en)
*
|
2005-01-21 |
2008-12-31 |
Genentech Inc |
Fixed dosing of her antibodies
|
CN101163501A
(zh)
*
|
2005-02-23 |
2008-04-16 |
梅里麦克制药股份有限公司 |
调节生物活性的双特异性结合剂
|
PE20070207A1
(es)
*
|
2005-07-22 |
2007-03-09 |
Genentech Inc |
Tratamiento combinado de los tumores que expresan el her
|
CN101321784A
(zh)
*
|
2005-10-11 |
2008-12-10 |
埃博灵克斯股份有限公司 |
针对egfr和igf-ir的纳米抗体tm和多肽
|
AR056857A1
(es)
*
|
2005-12-30 |
2007-10-24 |
U3 Pharma Ag |
Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos
|
WO2008027236A2
(en)
|
2006-08-30 |
2008-03-06 |
Genentech, Inc. |
Multispecific antibodies
|
CA2670315A1
(en)
|
2006-11-21 |
2008-11-20 |
The Regents Of The University Of California |
Anti-egfr family antibodies, bispecific anti-egfr family antibodies and methods of use thereof
|
US20080226635A1
(en)
|
2006-12-22 |
2008-09-18 |
Hans Koll |
Antibodies against insulin-like growth factor I receptor and uses thereof
|
EP3248617A3
(en)
|
2007-02-16 |
2018-02-21 |
Merrimack Pharmaceuticals, Inc. |
Antibodies against erbb3 and uses thereof
|
GB0807018D0
(en)
|
2008-04-17 |
2008-05-21 |
Fusion Antibodies Ltd |
Antibodies and treatment
|
EP2138511A1
(en)
*
|
2008-06-27 |
2009-12-30 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
HER3 as a determinant for the prognosis of melanoma
|
TWI461211B
(zh)
*
|
2009-03-20 |
2014-11-21 |
Genentech Inc |
抗-her抗體
|
EP2417159A1
(en)
|
2009-04-07 |
2012-02-15 |
Roche Glycart AG |
Bispecific anti-erbb-3/anti-c-met antibodies
|
TWI630916B
(zh)
*
|
2009-11-13 |
2018-08-01 |
第一三共歐洲公司 |
供治療或預防人表皮生長因子受體-3(her-3)相關疾病之藥料和方法
|
MY161909A
(en)
|
2009-12-22 |
2017-05-15 |
Roche Glycart Ag |
Anti-her3 antibodies and uses thereof
|
JP2012016491A
(ja)
|
2010-07-08 |
2012-01-26 |
Panasonic Electric Works Co Ltd |
往復式電気かみそり
|
US20130259867A1
(en)
*
|
2012-03-27 |
2013-10-03 |
Genentech, Inc. |
Diagnosis and treatments relating to her3 inhibitors
|
WO2014159638A1
(en)
*
|
2013-03-14 |
2014-10-02 |
Genentech, Inc. |
Predicting response to egfr inhibitors
|